AI Article Synopsis
- - The study aimed to determine the prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Antioquia, Colombia, during the years 2016 to 2018, using the Capture-Recapture Method across eight neurological care centers.
- - Out of 221 consultation histories analyzed, 169 patients with NMOSD were identified, resulting in a prevalence rate of 4.03 cases per 100,000 inhabitants, predominantly affecting women (87.5%) and Mestizo individuals (81.6%).
- - The findings suggest that Antioquia has one of the highest NMOSD prevalence rates globally, emphasizing the need for further research to better understand this condition within the Colombian population.
Article Abstract
Background: There are few epidemiological studies published in the world evaluating the prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD). The true prevalence of the disease is not known and the studies carried out are based on the diagnostic criteria used prior to 2015.
Objective: To determine the prevalence of NMOSD in Antioquia, from January 2016 to December 2018.
Methods: The prevalence of NMOSD in Antioquia was determined using the Capture-Recapture Method. Eight centers in the Department of Antioquia for the care of patients with neurological diseases were included. The data was collected between 2016 and 2018.
Results: A total of 221 consultation histories, 169 patients with a diagnosis of NMOSD were identified. The prevalence was 4.03 cases/100,000 inhabitants (95% confidence interval (CI) 3.3-4.8) of whom (87.5%), were women and the predominant race was Mestizo (81.6%). The most frequent initial presentation was optic neuritis (ON) (50.9%). Most of the patients had motor or visual disability (86.4%) and the treatment most used was Rituximab (47.9%).
Conclusion: The prevalence of NMOSD in Antioquia is one of the highest reported in the world, except for the French Antilles. More studies are required to know the prevalence of this disease in the Colombian population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2022.103677 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients.
Sci Rep
January 2025
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Abassia, Cairo, Egypt.
Some patients with neuromyelitis optica spectrum disorder (NMOSD)-like symptoms test negative for anti-aquaporin-4 (anti-AQP4) antibodies. Among them, a subset has antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a condition now termed MOG antibody-associated disease (MOGAD). MOGAD shares features with NMOSD, like optic neuritis and myelitis, but differs in pathophysiology, clinical presentation, imaging findings, and biomarkers.
View Article and Find Full Text PDFMOGAD and NMOSD: insights on patients' radiological and laboratory findings from a single UAE center.
Front Neurol
December 2024
Department of Neurology and Neurosurgery, Mcgill University, Montreal, QC, Canada.
Introduction: Although neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are rare diseases, they pose a significant burden on both society and the healthcare system. This study aims to discuss the demographics and patient characteristics of these diseases in a single center in the United Arab Emirates (UAE).
Methods: This is a retrospective, descriptive study that included patients with either NMOSD or MOGAD treated at Rashid Hospital, UAE during the period between January 2019 and January 2024.
The epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder in a US population.
Ann Clin Transl Neurol
December 2024
Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, Anschutz Medical Campus, University of Colorado School of Medicine, Aurora, Colorado, USA.
Objective: To define the epidemiology and clinical presentation of seropositive neuromyelitis optica spectrum disorder (NMOSD) in a large US health system.
Methods: We completed a retrospective observational study of adult patients in the University of Colorado Health System from 1 January 2011 to 31 December 2020, using Health Data Compass (HDC), a data warehouse that combines electronic health information with claims and public health data in Colorado. We screened HDC for patients with either (1) an abnormal aquaporin-4 IgG test or (2) any G36 ICD-10 code.
Background: Distinct clinical course patterns have been identified between AQP4-IgG-positive and AQP4-IgG-negative NMOSD patients.
Objectives: This study aimed to evaluate the differences between AQP4-IgG-seropositive and AQP4-IgG-seronegative NMOSD patients in a single centre in Argentina.
Methods: We performed a retrospective cross-sectional study of 108 NMOSD patients in the city of Buenos Aires, Argentina.
Optic neuritis in demyelinating diseases: study of 38 cases.
Arq Neuropsiquiatr
December 2024
Universidade Federal Fluminense, Faculdade de Medicina, Programa de Pós-graduação Stricto Sensu em Neurociências e Neurologia, Niterói RJ, Brazil.
Background: Optic neuritis is an inflammation of the optic nerve caused by genetic factors, external influences, and the activation of cross-reactive immune responses to infections.
Objective: To describe the clinical and epidemiological characteristics of patients presenting optic neuritis as the initial symptom of some demyelinating diseases, divided among multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG)-associated disorders (MOGADs).
Methods: Thirty-eight patients who had optic neuritis as their first symptom and later developed MS, NMOSD, or MOGADs were analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!